The Zhitong Finance App learned that CRO concept stocks had the highest gains. As of press release, Kingsley Biotech (01548) rose 9.16% to HK$43.38; Gloria Ying (06821) rose 3.81% to HK$155.4; Pharmaceuticals (02359) rose 2.44% to HK$210; Pharmaceuticals (02269) rose 2.31% to HK$53.1; Tiger Pharmaceuticals (03347) rose 1.15% to HK$45.62.
According to the news, on September 21, according to a Reuters report, the US Treasury is drafting new rules for biotechnology investment in China. Unlike the broad restrictions previously advocated by some members of the US Congress, the plan under discussion may focus on limiting pathogens and biotechnology that may be weaponized. This means that the new regulations will not uniformly ban all biomedical cross-border transactions. Innovative conventional anti-cancer drugs such as oncology ADCs and dual antibodies will allow overseas pharmaceutical companies to acquire pipelines and carry out authorized BD cooperation.
Citi published a research report saying that the bank held another expert conference call on the 24th to discuss the future of US policy involving Chinese companies' pharmaceutical licensing arrangements. It believes that the US has a positive outlook on pharmaceutical licensing policies originating in China, and has constructive views on innovative drugs and biotechnology. Nomura, on the other hand, said that China's pharmaceutical “15th Five-Year Plan” highlights innovation and globalization, which is beneficial to innovative pharmaceutical companies and CRDMOs.